BioNexus Gene Lab Corp.
BGLC
$5.38
-$0.04-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -616.20K | -623.30K | -348.30K | -1.35M | 199.10K |
| Total Depreciation and Amortization | 41.70K | 40.00K | 43.00K | 49.10K | 31.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.10K | 70.00K | -203.00K | -162.50K | -576.50K |
| Change in Net Operating Assets | -112.30K | -310.80K | 438.60K | -700.00 | -326.30K |
| Cash from Operations | -737.90K | -824.10K | -69.80K | -1.46M | -672.30K |
| Capital Expenditure | -21.50K | -9.10K | -4.00K | -199.20K | -1.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.10K | -6.60K | 498.20K | 16.10K | 65.10K |
| Cash from Investing | -28.50K | -15.60K | 494.20K | -183.10K | 63.30K |
| Total Debt Issued | -- | -- | -1.40K | -197.00K | 175.40K |
| Total Debt Repaid | -500.00 | -900.00 | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 141.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -500.00 | -- | 7.00K | -2.40K | -- |
| Cash from Financing | -1.00K | -900.00 | 146.60K | -199.40K | 175.40K |
| Foreign Exchange rate Adjustments | 215.20K | 43.10K | -409.60K | 565.20K | -42.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -552.20K | -797.50K | 161.40K | -1.28M | -476.50K |